Source comparison
MK-677 Interactions: Medication and Compound Comparison
MK-677 interactions span multiple pharmacological classes. This table outlines the most clinically significant combinations, the mechanism of interaction, and the practical research implication. Insulin sensitizers (metformin, berberine) MK-677 increases insul
This comparison does not assign a generated winner or score.
- MK-677 interactions span multiple pharmacological classes. This table outlines the most clinically significant combinations, the mechanism of interaction, and the practical research implication.
- Insulin sensitizers (metformin, berberine)
- MK-677 increases insulin resistance; sensitizers improve it. Opposing mechanisms
- Confounds metabolic endpoints; impossible to isolate effects
- Do not combine in metabolic research. Sequence with 4-week washout
- GLP-1 receptor agonists (semaglutide, tirzepatide)
- GLP-1 agonists improve insulin sensitivity and lower blood glucose; MK-677 raises both
- Directly opposing effects on glucose homeostasis and insulin signaling
- Incompatible for glucose or body composition research
- Corticosteroids (prednisone, dexamethasone)
- Both elevate cortisol or cortisol-like activity. Additive HPA axis activation
- Amplifies catabolic effects, immune suppression, and glucose dysregulation
- High risk. Avoid concurrent use in any research model
- Thyroid hormone (levothyroxine, liothyronine)
- MK-677 suppresses TSH and may lower free T3; exogenous thyroid attempts compensation
- Unstable thyroid axis; difficult to maintain euthyroid state during MK-677 administration
- Monitor thyroid panels weekly if combination is unavoidable
- Growth hormone secretagogues (CJC-1295, Ipamorelin)
- Overlapping GH stimulation pathways; additive GH and IGF-1 elevation
- Risk of supraphysiological GH levels, glucose intolerance, and edema
- Redundant. Select one GH-stimulating agent per protocol
- Beta-blockers (propranolol, atenolol)
- MK-677 may increase heart rate and blood pressure; beta-blockers lower both
- Cardiovascular endpoints confounded; unclear net hemodynamic effect
- Not recommended for cardiovascular research models
- MK-677 interactions with other research peptides depend on the target pathway. Compounds like BPC 157 Peptide and TB 500 Thymosin Beta 4 target tissue repair and angiogenesis mechanisms that do not directly overlap with ghrelin receptor agonism, making them potentially compatible in multi-agent protocols. Though cortisol elevation from MK-677 may still impair recovery kinetics that these peptides aim to enhance. Researchers exploring neuroprotection or cognitive enhancement using Dihexa or P21 should account for thyroid suppression as a confounding variable, since thyroid hormones are essential for neuroplasticity and synaptic function.